1. Introduction {#sec1}
===============

A considerable number of various illnesses are accounted for by DNA and RNA viruses in humans and animal hosts.^[@ref1]^ Herpes simplex virus type 1 (HSV-1), which is a type of DNA virus belonging to the herpes virus family, is incriminated in the infection of mucocutaneous epithelial cells and in the establishment of some ganglionic sensory latencies.^[@ref2]^ Acyclovir ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) has been referred to as the gold standard medication for the treatment of HSV infections.^[@ref3],[@ref4]^

![Chemical structures of some clinically used antiviral drugs.](ao0c01364_0001){#fig1}

In addition, human adenoviruses, which are another class of DNA-containing viruses, are responsible for various ocular, respiratory, and gastrointestinal tract infections.^[@ref5],[@ref6]^ Although there is no current FDA-approved medication protocol for the treatment of adenovirus infections, the broad-spectrum antiviral drug cidofovir could be used in some responsive patients.^[@ref7]−[@ref9]^

On the other hand, Coxsackievirus B4 (CV B4), hepatitis A virus (HAV), and hepatitis C virus (HCV) are a few examples of enveloped single-stranded RNA-containing viruses. Coxsackieviruses are commonly accused of causing viral myocarditis, accompanied with the development of pancreatitis, encephalitis, meningitis, pleurodynia, and hepatitis.^[@ref10],[@ref11]^ While there are curative direct-acting antivirals (DAAs) for HCV, there is no specific medication for both CV B4 and HAV. Among the DDA curative treatments of HCV are the protease inhibitor simprivir, NS5A inhibitor daclatasvir, and polymerase NS5B inhibitor sofosbuvir.^[@ref12],[@ref13]^

About half of the number of the clinically used antiviral drugs is nucleos(t)ides; hence, the improvement of the overall tolerability and pharmacokinetic profile is of a major priority in the conceptual design and development of newly synthesized antiviral agents.^[@ref14],[@ref15]^ One of the most successful strategies to surmount the poor bioavailability of nucleosides and to deliver the therapeutically active 5-monophosphate is to mask the polar 5-hydroxyl functionality with aryloxy triester phosphoramidate.^[@ref16],[@ref17]^ This methodology is known as "Protide" technology in which the bioavailable phosphoramidate prodrug, after absorption and distribution, releases its nucleoside monophosphate after two sequential hydrolytic events by an esterase-type enzyme such as cathepsin A and a phosphoramidase-type enzyme such as hint-1.^[@ref18],[@ref19]^ So far, sofosbuvir that was FDA-approved in late 2013 and tenofovir alafenamide that was FDA-approved in late 2015 for HIV are the only two phosphoramidate nucleotide prodrugs that are clinically used, and many others are now in different phases of clinical trials^[@ref20]^ ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).

Thioglycosides, where the anomeric carbon of the sugar motif is connected to the proper heterocyclic or any other aglycon by a sulfur atom through a thioether bond, have proven to be of biological interest. As a part of our current project to explore synthetic methods for the preparation of *S*-glycosylated derivatives of heterocyclic nitrogen bases, we have recently reported on the synthesis and anticancer and antiviral activities of a number of acyclic and heterocyclic thioglycosides that have an interesting cytotoxic activity such as cyanoethylene thioglycosides,^[@ref21],[@ref22]^ pyridine thioglcosides,^[@ref23],[@ref24]^ pyrimidine thioglycosides,^[@ref25]^ imidazole thioglycosides,^[@ref26]^ pyrazole thioglycosides,^[@ref27]^ triazole thioglycosides,^[@ref28]^ oxadiazole thioglycosides,^[@ref29]^ thiophene thioglycosides,^[@ref30]^ quinoline thioglycosides,^[@ref31]^ thienopyrazole thioglycosides,^[@ref32]^ and pyrazolopyrimidine thioglycosides.^[@ref33],[@ref34]^ We have reported that the thioglycosides of dihydropyridine shows a strong P-glycoprotein (Pgp) antagonist and has activity against human colon carcinoma cells.^[@ref35]^ In light of these findings and our previous reports, the purpose of this work was to design and synthesize the novel and first reported pyridine- and pyrimidine-based thioglycoside phosphoramidates as sofosbuvir thio-analogues.

Owing to the endless mutations and the emergence of numerous multidrug-resistant viral strains, the arena of developing novel broad-spectrum, less toxic, and bioavailable antiviral medicines is warmly welcoming new frontiers. Driven by the aforementioned facts and aiming to explore novel antiviral drug candidates of promising potency, selectivity, bioavailability, and safety profile, we have incorporated the phosphoramidate functionality to pyridine- and pyrimidine-based thioglycosides, exploiting the molecular hybridization and protide strategic approaches in the first reported thioglycoside phosphoramidates. It was suggested that such a combination is believed to give some insights into the effect of this drug latentation technique in improving the biological activity of thioglycosides in such a way that hopefully may offer affordable, synthetically accessible, and effective antiviral analogs.

2. Results and Discussion {#sec2}
=========================

2.1. Chemistry {#sec2.1}
--------------

The per-acetylated pyridine and pyrimidine-based thioglycosides **3a**, **3b**, **10**, **14a**, **14b**, **18a**, and **18b** have been synthesized through nucleophilic substitution coupling of tautomeric thiol-containing heterocyclic bases **1**, **13**, or **17** with the corresponding α-bromo-sugar **2a**, **2b**, or **9**. The glycosidic linkage that connects the heterocyclic base to the anomeric carbon of the sugar was through the sulfur atom of the thioamide moiety of the base rather than through the nitrogen atom, as depicted in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. This thioglycosidic connection was elucidated and confirmed by X-ray crystallography of compounds **5a** and **14b**, as shown in [Figures [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}.^[@ref36],[@ref37]^

![X-ray crystal structure of compound **5a**.](ao0c01364_0002){#fig2}

![X-ray crystal structure of compound **14b**.](ao0c01364_0003){#fig3}

![Synthesis of Pyridine Thioglycoside Derivatives **5a** and **5b**](ao0c01364_0005){#sch1}

![Synthesis of Pyridine Thioglycoside Phosphoramidate Derivatives **8a** and **8b**](ao0c01364_0006){#sch2}

![Proposed Mechanism for the Regioselective Phosphoramidate Coupling](ao0c01364_0007){#sch3}

The unprotected thioglycosides **5a**, **5b**, **11**, **15a**, **15b**, **19a**, and **19b** were uneventfully obtained by ammonolysis of the acetate esters under basic conditions of methanolic ammonia. The following regioselective phosphoramidate coupling was successfully achieved via the alkoxide generation of all of the unprotected hydroxyl groups of the sugar part of the nucleosides using the proper molar ratio of a strong base. In the current work, it was anticipated that the Grignard reagent isopropyl magnesium chloride would be sufficiently basic to abstract the protons from the free hydroxyl groups of the deacetylated nucleosides to furnish the desired alkoxide anions^[@ref38]^ ([Schemes [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"} and [4](#sch4){ref-type="scheme"}--[6](#sch6){ref-type="scheme"}).

![Synthesis of Pyridine Phosphoramidate Derivative **12**](ao0c01364_0008){#sch4}

![Synthesis of Pyrimidine Phosphoramidate Derivatives **16a** and **16b**](ao0c01364_0009){#sch5}

![Synthesis of Pyrimidine Thioglycoside Phosphoramidate Derivatives **20a** and **20b**](ao0c01364_0010){#sch6}

The preferential regioselectivity was essentially based on the differential nucleophilicity of the formed alkoxide. The most nucleophilic alkoxide that is capable of performing the required nucleophilic attack on the electrophilic center of the phosphoramidate phosphorus would be the primary alkoxide due to both electronic and steric effects that are believed to play roles in orientation of the phosphoramidate tail of the targeted nucleotides through the S~N~2 reaction, as proposed in [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}.

2.2. Antiviral Screening {#sec2.2}
------------------------

A preliminary antiviral screening was initially performed for eight different nucleos(t)ides of the newly synthesized analogs that comprise both pyridine and pyrimidine thioglycosides at either the free unprotected or phosphoramidated levels. These tested compounds are **5b**, **8a**, **8b**, **11**, and **12** of the pyridine-based analogs, among which compounds **5b** and **11** represent the unprotected nucleosides, while compounds **8a**, **8b**, and **12** are from the protide type. On the other hand, compounds **19a**, **20a**, and **20b** are the tested ones from the pyrimidine-based congeners, of which only compound **19a** represents the free unprotected analog, while both **20a** and **20b** are the phosphoramidate nucleotide analogs. These compounds were tested on both DNA- and RNA-containing viruses. Both adenovirus and HSV-1 are representatives of the DNA-containing viruses, while Coxsackie virus B4, hepatitis A virus, and HCV are representatives of the RNA-containing viruses.

### 2.2.1. Cytotoxicity Assay {#sec2.2.1}

Cytotoxicity assay was carried out via cell morphology evaluation using an inverted light microscope and cell viability test applying the trypan blue dye exclusion method where the nontoxic doses of the tested compounds were determined based on the assay on FRHK-4, Hep2, BGM, Vero, and Huh 7.5 cell lines prior the application on the targeted viruses. The values of the nontoxic doses of the tested compounds ranged from 70 to 100 μg/mL, as shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}. It could be inferred from the tabulated results of the nontoxic dose determination of the tested compounds that both compounds **5b** and **11** showed the highest safety profile that could participate in a relatively wider therapeutic index compared to the rest of compounds. The higher the nontoxic dose value, the higher the safety profile; therefore, compound **11** exhibited the safest profile among all the tested compounds with 100 μg/mL nontoxic dose against all the tested cell lines, except against BGM cell line, which showed a 90 μg/mL value. The second safest compound is **5b** that showed a 90 μg/mL nontoxic dose against all the tested cell lines, except against Hep2 cell line, which showed a 100 μg/mL value. On the other side, both compounds **19a** and **20b** showed the least safe dosing profile among the test compounds with 70--80 μg/mL nontoxic dose values against all the tested cell lines.

![Comparison between the percentages of viral load reduction of most potent compounds **5b**, **8a**, **8b**, **11**, **12**, **19a**, **20a**, and **20b**.](ao0c01364_0004){#fig4}

###### Nontoxic Doses of Tested Compounds on FRHK-4, Hep2, BGM, Vero, and Huh 7.5 Cell Lines

            nontoxic dose                    
  --------- --------------- ----- ---- ----- -----
  **5b**    90              100   90   90    90
  **8a**    80              90    80   90    90
  **8b**    80              80    80   80    80
  **11**    100             100   90   100   100
  **12**    80              90    80   90    80
  **19a**   70              80    70   80    80
  **20a**   90              90    90   90    90
  **20b**   70              80    70   80    80

### 2.2.2. Determination of Coxsackievirus B4 Titers Using Plaque Assay {#sec2.2.2}

The application of the previously determined nontoxic dilutions on different doses of the BGM cell lines measured the initial and final viral titers of Coxsackievirus B4 and, hence, the mean percentage reduction of viral titers. As shown in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, it could be revealed that both compounds **5b** and **11** exhibited the most promising antiviral activities among the tested compounds with 70% mean percentage reduction of the viral titer compared to 10--23.5% of the rest of the evaluated candidates. These two compounds underwent further investigations by determining their CC~50~ and IC~50~ values, showing very close activity profiles with 17 and 20 μg/100 μL values for CC~50~ and 4.5 and 6 μg/100 μL values for IC~50~ of compounds **5b** and **11**, respectively ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}).

###### Nontoxic Doses of Tested Compounds on CBV4, HAV HM175, HAdV7, HSV-1, and HCVcc Genotype 4 Cell Lines

            nontoxic dose                        
  --------- --------------- ------ ------ ------ ------
  **5b**    70              30     20     90     37.7
  **8a**    20              23.5   13.3   30     20
  **8b**    10              10     10     30     30
  **11**    70              30     20     83.3   50
  **12**    23.5            20     10     30     30
  **19a**   10              20     10     20     20
  **20a**   20              20     10     20     20
  **20b**   10              20     10     20     33.3

###### Determination of the Antiviral CC~50~ and IC~50~ of Nontoxic Doses of Compounds **5b** and **11** against Coxsackievirus B4

  compound no.   mean% reduction   nontoxic dose (μg/100 μL)   CC~50~ (μg/100 μL)   IC~50~ (μg/100 μL)   SI
  -------------- ----------------- --------------------------- -------------------- -------------------- -----
  **5b**         90                9                           17                   4.5                  3.8
  **11**         83.3              10                          20                   6                    3.3

### 2.2.3. Determination of HAV HM175 and Adenovirus 7 Titers Using Plaque Assay {#sec2.2.3}

The values of mean percentage reduction of all the tested compounds against both hepatitis A virus HM 175 strain and adenovirus 7 did not reflect notable activity. These values were ranging between 10 and 30 mean percentage reductions against hepatitis A virus HM 175 strain and between 10 and 20 mean percentage reductions against adenovirus 7, as shown in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}.

### 2.2.4. Determination of Herpes Simplex Virus Type 1 Titers Using Plaque Assay {#sec2.2.4}

Furthermore, both compounds **5b** and **11** showed the most prominent activity among all the tested compounds against herpes simplex virus type 1 with mean percentage reduction values of 90 and 83.3%, respectively, as depicted in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}. For these two most active compounds, CC~50~, IC~50~, and SI values were assessed in comparison with acyclovir. The CC~50~ values of compounds **5b** and **11** were 17 and 16 μg/100 μL, respectively, versus 0.28 μg/100 μL for acyclovir. On the other hand, the IC~50~ values of **5b** and **11** were 6.3 and 6.6 μg/100 μL, respectively, versus 0.07 μg/100 μL for acyclovir, as shown in [Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}.

###### Determination of the Antiviral CC~50~, IC~50~, and SI of Nontoxic Doses of Compounds **5b** and **11** against Herpes Simplex Virus

  compound no.   mean% reduction   nontoxic dose (μg/100 μL)   CC~50~ (μg/100 μL)   IC~50~ (μg/100 μL)   SI
  -------------- ----------------- --------------------------- -------------------- -------------------- -----
  **5b**         70                9                           17                   6.3                  2.7
  **11**         70                9                           16                   6.6                  2.4
  acyclovir      90.6              0.15                        0.28                 0.07                 4

#### 2.2.4.1. Herpes Simplex Polymerase (HSP) Enzyme Assay for Compounds **5b**, **11**,and Acyclovir {#sec2.2.4.1}

Despite showing lower potency of both compounds **5b** and **11** than acyclovir in the enzyme assay against herpes simplex polymerase, the combination of **11** with acyclovir elicited a notable synergistic activity in comparison with acyclovir alone ([Table [5](#tbl5){ref-type="other"}](#tbl5){ref-type="other"}). This finding of potential synergism could recommend a highly effective combination therapy.

###### HSP Enzyme Assay % Inhibition and IC~50~ Values for Compounds **5b** and **11** and Their Combination with Acyclovir

  compound no.         % inhibition   HSP IC~50~ (μg/mL)
  -------------------- -------------- --------------------
  **5b**               77             9.99
  **11**               81             7.92
  acyclovir            84             4.78
  **5b** + acyclovir   84.6           4.34
  **11** + acyclovir   88             2.64

### 2.2.5. Antiviral Bioassay of Tested Materials against ED-43/SG-Feo (VYG) Replicon of Hepatitis C Virus Genotype 4a {#sec2.2.5}

Compound **11** exhibited a moderate antiviral activity against HCVcc genotype 4 with just 50% mean percentage reduction for which both CC~50~ and IC~50~ values were assessed as 19 and 10 μg/100 μL, respectively, as tabulated in [Table [6](#tbl6){ref-type="other"}](#tbl6){ref-type="other"}

###### CC~50~ and IC~50~ Values of Compound **11** against HCVcc Genotype 4

  compound no.   mean % reduction   nontoxic dose (μg/100 μL)   CC~50~ (μg/100 μL)   IC~50~ μg/100 μL)   SI
  -------------- ------------------ --------------------------- -------------------- ------------------- -----
  **11**         50%                10                          19                   10                  1.9

Furthermore, both compounds **5b** and **11** were evaluated for their DDA (direct-acting antiviral activity) by measuring enzyme-inhibitory activities against two potential targets of HCV, namely, NS5B (nonstructural protein 5B) and HCV protease, in comparison to sofosbuvir. These enzyme assay results were in accordance to the previously mentioned data with respect to the superiority of compound **11** over **5b** with respect to its potency and potential efficacy against HCV-RNA genome ([Tables [7](#tbl7){ref-type="other"}](#tbl7){ref-type="other"} and [8](#tbl8){ref-type="other"}).

###### HCV NS5B Enzyme Assay % Inhibition and IC~50~ Values for Compounds **5b** and **11** and Their Combination with Sofosbuvir

  compound no.        % inhibition   HCV NS5B IC~50~ (μg/mL)
  ------------------- -------------- -------------------------
  **5b**              52             17.83 ± 1.09
  **11**              83             4.48 ± 0.9
  sofosbuvir (sov.)   87             2.06 ± 0.34
  **5b** + sov.       68             7.65 ± 0.72
  **11** + sov.       90             1.81 ± 0.29

###### HCV Protease Enzyme Assay % Inhibition and IC~50~ Values for Compounds **5b** and **11** and Their Combination with Sofosbuvir

  compound no.    % inhibition   HCV protease IC~50~ (μg/mL)
  --------------- -------------- -----------------------------
  **5b**          41             19.54 ± 1.3
  **11**          85             3.18 ± 0.27
  **5b** + sov.   61             8.23 ± 0.61
  **11** + sov.   91             1.04 ± 0.08

The remarkable synergistic potentiation upon combining compound **11** and sofosbuvir recommends a promising combination therapy that may lead to a pan-genotypic combotherapy.

3. Conclusions {#sec3}
==============

We have achieved the first report of pyridine and pyrimidine thioglycoside phosphoramidates as sofosbuvir thio-analogues. The structures of the synthesized compounds were confirmed by the spectral data, and the thioglycosidic linkage was elucidated by X-ray crystallography. The compounds were evaluated for their antiviral activities against different viral cell lines, namely, adenovirus 7, HAV (hepatitis A) HM175, Coxsackievirus B4, and HSV-1 (herpes simplex virus type 1) in addition to the antiviral bioassay against ED-43/SG-Feo (VYG) replicon of HCV (hepatitis C virus) genotype 4a. Compounds **5b** and **11** showed notable antiviral activity against Coxsackievirus B4 and herpes simplex. Only compound **11** showed a moderate activity against HCV especially with the synergistic combination with sofosbuvir that may lead to a powerful combination therapy. All the tested thioglycoside protides showed low to moderate activities against the tested viruses; however, retaining some antiviral potential especially for **8b** and **12**, which are the prodrugs of **5b** and **11**, respectively, recommends their prolonged activities and the expected better pharmacokinetic profile. This may recommend further investigational pharmacokinetic studies in the combinations of sofosbuvir with the corresponding phosphoramidate prodrugs **5b** and **11.**

4. Experimental Part {#sec4}
====================

All melting points were measured on a Gallenkamp melting point apparatus. The ^1^H NMR and ^13^C NMR spectra were measured on a Jeol-500 MHz spectrometer in DMSO-*d*~6~ or CDCl~3~ using Si(CH~3~)~4~ as an internal standard at the Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. Elemental analyses were carried out at the Microanalytical Unit, Faculty of Science, Cairo University. Progress of the reactions was monitored by TLC using aluminum sheets coated with silica gel F254 (Merck). Viewing under a short-wavelength UV lamp effected detection. X-ray data were measured at the Institut fur Anorganische und Analytische Chemie, Technische Universitat Braunschweig, Braunschweig, Germany. Pyridine-2(1*H*)-thiones **1**, **13**, and **17** and their corresponding thioglycosides were prepared following our literature procedures.^[@ref39]^

4.1. General Procedure for the Synthesis of Acetylated Thioglycosides **3a**, **3b**, **10**, **14a**, **14b**, **18a**, and **18b** {#sec4.1}
------------------------------------------------------------------------------------------------------------------------------------

To a solution of pyridinethione **1** (0.01 mol) in dry DMF (20 mL), NaH (15 mmol) was added portion-wise through 15 min and the solution was stirred at room temperature for another 30 min. Then, a solution of 2,3,4,6-tetra-*O*-acetyl-α-[d]{.smallcaps}-gluco (or galacto)pyronosyl bromide was dropped within 30 min and the reaction mixture was stirred at room temperature until completion (TLC, 3--6 h). After completion, the reaction mixture was poured on ice water to remove the potassium bromide formed. The product was filtered off, dried, and crystallized from ethanol.

4.2. General Procedure for the Synthesis of Unprotected Pyridine Thioglycosides **5a**, **5b**, and **11** and Pyrimidine Thioglycosides **15a**, **15b**, **19a**, and **19b** {#sec4.2}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dry gaseous ammonia was passed through a solution of protected glycosides **3a**, **3b**, **10**, **14a**, **14b**, **18a**, or **18b** in dry methanol (20 mL) at 0 °C for 10 min. Then, the mixture was stirred at 0 °C for 2 to 6 h. The mixture was evaporated under reduced pressure at 60 °C to give a solid residue, which was crystallized from ethanol.

4.3. General Procedure for the Synthesis of Pyrimidine/Pyridine Phosphoramidate Nucleotides {#sec4.3}
-------------------------------------------------------------------------------------------

A flame-dried flask kept under a nitrogen atmosphere was loaded with the unprotected pyridine thioglycosides **5a**, **5b**, and **11** or pyrimidine thioglycosides **15a**, **15b**, **19a**, and **19b** (1 molar ratio) at 25 °C THF, the formed suspension was allowed to stir and cool down to −5 °C, and then iPrMgCl (1.88 M in THF) was added in a dropwise manner through a dropping funnel without exceeding 0 °C for a period of 1 h. At the end of the addition, bring the temperature to 15--18 °C in about 30 min and keep the reaction mixture under these conditions for 30 min. Cool down to 0--5 °C and, in the meantime, prepare solution of **7** in THF by adding solution **7** to the main reaction mixture through a dropping funnel without exceeding 5 °C in a period of 1--2 h. At the end of dropping, wash the dropping funnel with THF and keep the reaction mixture under stirring at 0--5 °C for about 18--22 h, as monitored in TLC. When the reaction is over, add to the reaction mixture at 0--5 °C a solution of ammonium chloride, leave the reaction temperature to increase to about 10 °C, and then add a few drops of HCl. Bring the mixture to 25 °C, separate the phases, separate the upper THF organic layer, distill it out under vacuum, then add it to the residue DCM, wash it six times with 2% sodium carbonate, and then wash it with 0.5 N HCl and with brine. Filter the organic layer on Celite/charcoal pad and wash the filter with DCM, distill it out under vacuum, and crystallize the residue from the appropriate solvent.

### 4.3.1. 3-Cyano-4,6-dimethyl-2-(β-[d]{.smallcaps}-glucopyranosylthio)pyridine (**5a**) {#sec4.3.1}

White powder; EtOH; yield, 75%; mp 226--228 °C; IR (KBr, cm^--1^): υ 3462 (OH), 2968 (CH), 2206 (CN), 1601 (C=N); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 2.48 (s, 3H, CH~3~), 2.53 (s, 3H, CH~3~), 3.14--3.18 (m, 2H, H-6′, H-6″), 3.23--3.26 (m, 2H, H-4′, H-5′), 3.99--3.41 (m, 1H, H-3′), 3.59--3.61 (m, 1H, H-2′), 4.44 (t, 1H, *J*~OH--H-6′~ = 5.6 Hz, D~2~O exch., 6′--OH), 4.99 (d, 1H, *J* = 4.8 Hz, D~2~O exch., OH), 5.19 (d, 1H, *J* = 4.0 Hz, D~2~O exch., OH), 5.49 (dd, 1H, *J* = 6.0, 8.4 Hz, D~2~O exch., OH), 5.55 (d, 1H, *J*~1′--2′~ = 10.0 Hz, H-1′), 7.28 (s, 1H, pyridine H-5); ^13^C NMR: δ 22.41(CH~3~), 27.23 (CH~3~), 62.89 (C-6′), 73.51 (C-5′), 74.68 (C-4′), 77.54 (C-3′), 83.28 (C-2′), 86.39 (C-1′), 111.24 (C-3), 117.42 (CN), 122.61 (C-5), 158.12 (C-4), 162.26 (C-6), 164.53 (C-2). Anal. calcd. for C~14~H~18~N~2~O~5~S (326.37): C, 51.52; H, 5.56; N, 8.58; S, 9.82%. Found: C, 51.32; H, 5.34; N, 8.45; S, 9.65%.

### 4.3.2. 3-Cyano-4,6-dimethyl-2-(β-[d]{.smallcaps}-galactopyranosylthio)pyridine (**5b**) {#sec4.3.2}

White powder; EtOH; yield, 83%; mp 199--210 °C; IR (KBr, cm^--1^): υ 3452 (OH), 2939 (CH), 2211 (CN), 1597 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.41 (s, 3H, CH~3~), 2.49 (s, 3H, CH~3~), 3.42--3.49 (m, 2H, 2H-6′), 3.53--3.59 (m, 1H, H-5′), 3.75 (t, 1H, *J*~4′--3′~ = 3.5 Hz, *J*~4′--5′~ = 3.7 Hz, H-4′), 4.33 (t, 1H, *J*~3′--2′~ = 9.1 Hz, *J*~3′--4′~ = 3.5 Hz, H-3′), 4.49 (t, 1H, *J*~2′--1′~ = 8.3 Hz, *J*~2′--3′~ = 9.2 Hz, H-2′), 4.94 (s, D~2~O exch., 3H, 2′--OH, 3′--OH, and 4′--OH), 5.34 (s, D~2~O exch., 1H, 6′--OH), 5.51 (d, 1H, *J*~1′--2′~ = 10.5 Hz, H-1′), 7.13 (s, 1H, pyridine H-5); ^13^C NMR: δ 23.06 (CH~3~), 23.66 (CH~3~), 61.97 (C-6′), 75.32 (C-5′), 77.11 (C-4′), 79.89 (C-3′), 83.44 (C-2′), 86.45 (C-1′), 108.63 (C-3), 116.48 (CN), 125.21 (C-5), 155.67 (C-4), 163.87 (C-6), 166.72 (C-2). Anal. calcd. for C~14~H~18~N~2~O~5~S (326.37): C, 51.52; H, 5.56; N, 8.58; S, 9.82%. Found: C, 51.32; H, 5.34; N, 8.45; S, 9.65%.

### 4.3.3. 4,6-Dimethyl-2-(β-[d]{.smallcaps}-arabinoofuranosylthio) Nicotinonitrile (**11**) {#sec4.3.3}

White powder; EtOH; yield, 77%; mp 164 °C; IR (KBr, cm^--1^): υ 3436 (OH), 2964 (CH), 2206 (CN), 1596 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.35 (s, 3H, CH~3~), 2.42 (s, 3H, CH~3~), 3.62--3.65 (m, 2H, H-6′), 3.96--3.97 (m, 1H, H-5′), 4.14 (t, 1H, *J*~4′--3′~ = 8.4 Hz, *J*~4′--5′~ = 5.6 Hz, H-4′), 4.99 (s, D~2~O exch., 3H, 2′--OH, 3′--OH, and 4′--OH), 5.14 (t, 1H, *J*~3′--2′~ = 9.3 Hz, *J*~3′--4′~ = 8.9 Hz, H-3′), 5.51 (t, 1H *J*~2′--1′~ = 9.1 Hz, *J*~2′--3′~ = 9.2 Hz, H-2′), 6.08 (d, 1H, *J*~1′--2′~ = 10.8 Hz, H-1′), 7.22 (s, pyridine H-5). Anal. calcd. for C~13~H~16~N~2~O~4~S (296.34): C, 52.69; H, 5.44; N, 9.45; S, 10.82%. Found: C, 52.56; H, 5.35; N, 9.32; S, 10.75%.

### 4.3.4. 4,6-Dimethyl-2-(β-[d]{.smallcaps}-glucopyranosylthio)pyrimidine (**15a**) {#sec4.3.4}

White powder; yield, 79%; mp 156 °C; IR (KBr, cm^--1^): υ 3454 (OH), 2947 (CH), 1595 (C=N); ^1^H NMR (500 MHz, CDCl~3~): δ 2.36 (s, 6H, 2CH~3~), 3.89--3.91 (m, 2H, 2H-6′), 4.12--4.13 (m, 1H, H-5′), 4.24 (t, 1H, *J*~4′--3′~ = 8.4 Hz, *J*~4′--5′~ = 9.2 Hz, H-4′), 4.69 (d, 1H, *J* = 6.9 Hz, D~2~O exch., 6′--OH), 4.75 (d, 1H, *J* = 6.9 Hz, D~2~O exch., OH), 5.13 (t, 1H, *J*~3′--2′~ = 9.1 Hz, *J*~3′--4′~ = 8.9 Hz, H-3′), 5.24 (s, 2H, D~2~O exch., 2OH), 5.32(t, 1H, *J*~2′--1′~ = 9.2 Hz, *J*~2′--3′~ = 8.7 Hz, H-2′), 5.60 (d, 1H, *J*~1′--2′~ = 10.3 Hz, H-1′), 6.86 (s, 1H, pyridine H-5). Anal. calcd. for C~12~H~18~N~2~O~5~S (302.5): C, 47.67; H, 6.00; N, 9.27; S, 10.61%. Found: C, 47.55; H, 6.12; N, 9.16; S, 10.52%.

### 4.3.5. 4,6-Dimethyl-2-(β-[d]{.smallcaps}-galactopyranosylthio)pyrimidine (**15b**) {#sec4.3.5}

White powder; yield, 95%; mp 180 °C; IR (KBr, cm^--1^): υ 3473 (OH), 2926 (CH), 1595 (C=N); ^1^H NMR (500 MHz, CDCl~3~): δ 2.32 (s, 6H, 2CH~3~), 3.41--3.43 (m, 2H, 2H-6′), 3.75--3.76 (m, 2H, H-5′), 4.32 (t, 1H, *J*~4′--3′~ = 3.4 Hz, *J*~4′--5′~ = 3.8 Hz, H-4′), 4.93 (t, 1H, *J*~3′--2′~ = 9.3 Hz, *J*~3′--4′~ = 3.6 Hz, H-3′), 4.89 (s, D~2~O exch., 3H, 2′--OH, 3′--OH, and 4′--OH), 4.92 (s, D~2~O exch., 1H, 6′--OH), 5.21 (t, 1H, *J*~2′--1′~ = 8.3 Hz, *J*~2′--3′~ = 9.2 Hz, H-2′), 5. 42 (d, 1H, *J*~1′--2′~ = 8.9 Hz, H-1′), 7.21 (s, 1H, pyridine H-5); ^13^C NMR: δ 24.13 (2CH~3~), 62.64 (C-6′), 74.42 (C-5′), 78.63 (C-4′), 79.66 (C-3′), 84.53 (C-2′), 85.45 (C-1′), 108.63 (C-3), 116.48 (CN), 125.21 (C-5), 155.67 (C-4), 163.87 (C-6), 166.72 (C-2). Anal. calcd. for C~12~H~18~N~2~O~5~S (302.5): C, 47.67; H, 6.00; N, 9.27; S, 10.61%. Found: C, 47.55; H, 6.12; N, 9.16; S, 10.52%.

### 4.3.6. Ethyl-4-methyl-2-(β-[d]{.smallcaps}-glucopyranosylthio)-6-phenylpyrimidine-5-carboxylate (**19a**) {#sec4.3.6}

White powder; EtOH; yield, 82%; mp 146 °C; IR (KBr, cm^--1^): υ 3429 (OH), 3045 (CH aromatic), 2933 (CH), 2224 (CO), 1592 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.28 (t, 3H, CH~3~), 3.01 (s, 3H, CH~3~), 3.23--3.24 (m, 1H, H-6′), 3.49--3.51 (m. 1H, H-6″), 3.71--3.73 (m, 1H, H-5′), 3.86--3.88 (m, 2H, H-3′, H-4′), 4.21 (q, 2H, CH~2~), 4.56 (t, 1H, *J*~2′--1′~ = 8.6 Hz, *J*~2′--3′~ = 9.2 Hz, H-2′), 5.11 (s, 4H, D~2~O exch., 2′--OH, 3′--OH, 4′--OH, and 6′--OH), 5.26 (d, 1H, *J*~1′--2′~ = 8.6 Hz, H-1′), 7.36--7.56 (m, 5H, C~6~H~5~); ^13^C NMR: δ 16.57 (CH~3~), 23.42 (CH~2~), 62.43 (C-6′), 71.34 (C-5′), 76.43 (C-4′), 79.66 (C-3′), 81.26 (C-2′), 83.67 (C-1′), 113.63 (C-5), 128.45--139.47 (6C, Ar-C), 164.54 (C-4), 167.42 (CO), 169.86 (C-6), 176.51 (C-2). Anal. calcd. for C~20~H~24~N~2~O~7~S (436.48): C, 55.03; H, 5.54; N, 6.42; S, 7.35%. Found: C, 55.13; H, 5.46; N, 6.30; S, 7.28%.

### 4.3.7. Ethyl-4-methyl-2-(β-[d]{.smallcaps}-galactopyranosylthio)-6-phenylpyrimidine-5-carboxylate (**19b**) {#sec4.3.7}

White powder; EtOH; yield, 86%; mp 173--174 °C; IR (KBr, cm^--1^): υ 3456 (OH), 3048 (CH aromatic), 2949 (CH), 2226 (CO), 1595 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.34 (t, 3H, CH~3~), 3.13 (s, 3H, CH~3~), 3.34--3.36 (m, 2H, H-6′, H-6″), 3.55--3.56 (m, 1H, H-5′), 3.66--3.68 (m, 2H, H-3′, H-4′), 4.02 (q, 2H, CH~2~), 4.48 (t, 1H, *J*~2′--1′~ = 9.8 Hz, *J*~2′--3′~ = 9.1 Hz, H-2′), 4.56 (t, 1H, *J*~OH--H-6″~ = 5.6 Hz, D~2~O exch., 6′--OH), 5.01 (s, 3H, D~2~O exch., 2′--OH, 3′--OH, and 4′--OH), 5.34 (d, 1H, *J*~1′--2′~ = 9.8 Hz, H-1′), 7.35--7.58 (m, 5H, C~6~H~5~). Anal. calcd. for C~20~H~24~N~2~O~7~S (436.48): C, 55.03; H, 5.54; N, 6.42; S, 7.35%. Found: C, 55.13; H, 5.46; N, 6.30; S, 7.28%.

### 4.3.8. Isopropyl-2-((((3*S*,4*R*,5*S*,6*S*)-6-(3-cyano-4,6-dimethylpyridin-2-ylthio)-3,4,5-trihydroxy-tetrahydro-2*H*-pyran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (**8a**) {#sec4.3.8}

White powder; EtOH; yield, 91%; mp 148 °C; IR (KBr, cm^--1^): υ 3419 (OH), 3268 (NH), 3028 (CH aromatic), 2955 (CH), 2229 (CO), 1602 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.19 (d, 3H, *J* = 6.2 Hz, CH~3~), 1.32 (d, 6H, *J* = 6.4 Hz, *J* = 5.6 Hz, 2CH~3~), 2.41 (s, 3H, CH~3~), 2.61 (s, 3H, CH~3~), 3.65 (d, H, *J* = 6.6 Hz, CH), 3.82 (m, 2H, H-6′), 4.01 (d, 2H, *J* = 5.8 Hz, CH~2~), 4.52 (m, 2H, H-4′, H-5′), 4.63 (s, D~2~O exch., 3H, 2′--OH, 3′--OH, and 4'--OH), 4.82 (m, 1H, CH), 5.13 (t, 1H*, J*~3′--2′~ = 9.2 Hz, *J*~3′--4′~ = 3.2 Hz, H-3′), 5.23 (t, 1H, *J*~2′--1′~ = 9.4 Hz, *J*~2′--3′~ = 9.3 Hz, H-2′), 5.42 (d, 1H, *J*~1′--2′~ = 9.4 Hz, H-1′), 7.31--7.93 (m, 6H, C~6~H~5~, pyridine H-5), 11.34 (s, 1H, NH). Anal. calcd. for C~26~H~34~N~3~O~9~PS (595.60): C, 52.43; H, 5.75; N, 7.06; S, 5.38%. Found: C, 52.36; H, 5.66; N, 7.16; S, 5.30%.

### 4.3.9. Isopropyl-2-((((3*R*,4*R*,5*S*,6*S*)-6-(3-cyano-4,6-dimethylpyridin-2-ylthio)-3,4,5-trihydroxytetrahydro-2*H*-pyran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (**8b**) {#sec4.3.9}

White powder; EtOH; yield, 78%; mp 149 °C; IR (KBr, cm^--1^): υ 3415 (OH), 3277 (NH), 3041 (CH aromatic), 2984 (CH), 2227 (CO), 1600 (C=N); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 1.26 (d, 3H, CH~3~), 1.31 (d, 6H, 2CH~3~), 2.41 (s, 6H, 2CH~3~), 3.34--3.49 (m, 4H, H-4′, H-5′, 2H-6′), 3.57 (t, 1H, *J*~3′--2′~ = 9.3 Hz, *J*~3′--4′~ = 3.1 Hz, H-3′), 3.74--3.75 (m, 1H, CH), 4.49--4.52 (m, 2H, CH~2~), 4.94 (s, D~2~O exch., 3H, 2′--OH, 3′--OH, and 4′--OH), 5.12 (m, 1H, CH), 5.32 (t, 1H, *J*~2′--1′~ = 9.1 Hz, *J*~2′--3′~ = 9.2 Hz, H-2′), 5.52 (d, 1H, *J*~1′--2′~ = 10.2 Hz, H-1′), 7.41--7.63 (m, 5H, C~6~H~5~), 8.08 (s, 1H, pyridine H-5), 10.26 (s, 1H, NH). Anal. calcd. for C~26~H~34~N~3~O~9~PS (595.60): C, 52.43; H, 5.75; N, 7.06; S, 5.38%. Found: C, 52.36; H, 5.66; N, 7.16; S, 5.30%.

### 4.3.10. Isopropyl-2-(((3*R*,4*R*,5*R*,6*S*)-6-(3-cyano-4,6-dimethylpyridin-2-ylthio)-4,5-dihydroxytetrahydro-2*H*-pyran-3-yloxy)(phenoxy)phosphorylamino)propanoate (**12**) {#sec4.3.10}

White powder; EtOH; yield, 88%; mp 144 °C; IR (KBr, cm^--1^): υ 3427 (OH), 3271 (NH), 3047 (CH aromatic), 2982 (CH), 2231 (CO), 1596 (C=N); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 1.02 (d, 3H, *J* = 6.4 Hz, CH~3~), 1.12 (d, 6H, *J* = 6.3 Hz, 2CH~3~), 2.31 (s, 6H, 2CH~3~), 2.4 (s, 3H, CH~3~), 3.35--3.36 (m, 2H, H-5′), 3.62--3.64 (m, 3H, H-2′, H-3′, H-4′), 3.71--3.72 (m, 1H, CH), 3.9 8--4.01 (m, 2H, CH~2~), 4.52 (d, 1H, *J*~1′--2′~ = 9.5 Hz, H-1′), 4.92--4.93 (m, 1H, CH), 5.11--5.21 (s, D~2~O exch., 2H, 2′--OH, 3′-OH), 724--7.35 (m, 5H, C~6~H~5~), 8.33 (s, 1H, pyrimidine H-5), 10.33 (s, 1H, NH). Anal. calcd. for C~25~H~32~N~3~O~8~PS (565.58): C, 53.09; H, 5.70; N, 7.43; S, 5.67%. Found: C, 53.15; H, 5.62; N, 7.36; S, 5.56%.

### 4.3.11. Isopropyl-2-(((((2*R*,3*S*,4*S*,5*R*,6*S*)-6-((4,6-dimethylpyrimidin-2-yl)thio)-3,4,5-trihydroxytetrahydro-2*H*-pyran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-propanoate (**16a**) {#sec4.3.11}

White powder; yield, 95%; mp 160 °C; ^1^H NMR (500 MHz, CDCl~3~): δ 1.23 (d, 3H, CH~3~), 1.34 (d, 6H, 2CH~3~), 2.35 (s, 3H, CH~3~), 2.46 (s, 3H, CH~3~), 3.62 (s, H, OH), 3.71 (s, H, OH), 3.83 (s, H, OH), 3.92--3.94 (m, 2H, 2H-6′), 4.28--4.31 (m, 1H, H-5′), 4.92 (d, 1H, H-4′), 5.52--5.53 (m, 2H, H-3′, H-1′), 5.42 (d, 1H, H-2′), 7.66 (s, 1H, Ar-H), 7.35--7.67 (m, 6H, Ar-- H). Anal. calcd. for C~24~H~34~N~3~O~9~PS (571.58): C, 50.43; H, 6.00; N, 7.35; S, 5.61%. Found: C, 50.35; H, 6.16; N, 7.24; S, 5.55%.

### 4.3.12. Isopropyl-2-(((((2*R*,3*S*,4*S*,5*R*,6*S*)-6-((4,6-dimethylpyrimidin-2-yl)thio)-3,4,5-trihydroxytetrahydro-2*H*-pyran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-propanoate (**16b**) {#sec4.3.12}

White powder; yield, 95%; mp 152 °C; ^1^H NMR (500 MHz, CDCl~3~): δ 1.23 (d, 3H, CH~3~), 1.32 (d, 6H, 2CH~3~), 2.14(s, 3H, CH~3~), 2.25 (s, 3H, CH~3~), 3.41 (s, H, OH), 3.54 (s, H, OH), 3.62 (s, H, OH), 3.96 (m, 2H, 2H-6′), 4.02 (m, 1H, H-5′), 4.43 (d, 1H, H-4′), 4.61 (m, 2H, H-3′, H-1′), 4.94 (d, 1H, H-2′), 6.82 (s, H, Ar-H), 7.25--7.91 (m, 6H, Ar-H); ^13^C NMR: δ 21.02 (CH~3~), 21.62 (2CH~3~), 23.84 (2CH3), 38.82 (CH), 61.29 (C-6′), 69.14 (C-5′), 69.48 (C-4′), 70.32 (C-3′), 79.45 (C-2′), 84.90 (C-1′), 116.54 (C-5), 153.31 (6C, Ar-C), 167.39 (C-4, C-6), 169.15 (C-2). Anal. calcd. for C~24~H~34~N~3~O~9~PS (571.58): C, 50.43; H, 6.00; N, 7.35; S, 5.61%. Found: C, 50.35; H, 6.16; N, 7.24; S, 5.55%.

### 4.3.13. Isopropyl-2-(((((2*R*,3*S*,4*S*,5*R*,6*S*)-6-ethyl((hydroxymethyl)-2*H*-pyran-2-ylthio)-4-methyl-6-phenylpyrimidine-5-carboxylate)-3,4,5-trihydroxytetrahydro-2*H*-pyran-2-yl)methoxy)(phenoxy)phosphoryl) amino)propanoate (**20a**) {#sec4.3.13}

White powder; yield, 89%; mp 138 °C; IR (KBr, cm^--1^): υ 3437 (OH), 3266 (NH), 3064 (CH aromatic), 2969 (CH), 2235 (CO), 1599 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.23 (d, 3H, CH~3~), 1.34 (d, 6H, 2CH~3~), 2.45 (t, 3H, CH~3~), 4.26 (q, 2H, CH~2~), 3.35 (s, 1H, 6′--OH), 3.47 (s, 1H, OH), 3.52 (s, 1H, OH), 3.74--3.76 (m, 2H, 2H-6′), 4.13--4.15 (m, 2H, CH~2~), 4.34--4.36 (m, 1H, H-5′), 4.92 (d, 1H, H-4′), 5.52--5.54 (m, 2H, H-3′, H-1), 5.64 (d, 1H, H-2′), 7.35--7.76 (m, 10H, Ar-H), 10.45 (s, 1H). Anal. calcd. for C~32~H~40~N~3~O~11~PS (705.71): C, 54.46; H, 5.71; N, 5.95; S, 4.54%. Found: C, 54.36; H, 5.65; N, 5.84; S, 4.42%.

### 4.3.14. Isopropyl-2-(((((2*R*,3*S*,4*S*,5*R*,6*R*)-6-ethyl((hydroxymethyl)-2*H*-pyran-2-ylthio)-4-methyl-6-phenylpyrimidine-5-carboxylate)-3,4,5-trihydroxytetrahydro-2*H*-pyran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate (**20b**) {#sec4.3.14}

White powder; yield, 98.5%; mp 134 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.24 (d, 3H, CH~3~), 1.32 (d, 6H, 2CH~3~), 2.44 (t, 3H, CH~3~), 2.52 (s, 3H, CH~3~), 4.21 (q, 2H, CH~2~), 3.34 (s, H, OH), 3.45 (s, H, OH), 3.52 (s, H, OH), 3.91 (m, 2H, 2H-6′), 4.23--4.25 (m, 1H, H-5′), 4.92 (d, 1H, H-4′), 5.52--5.54 (m, 2H, H-3′, H-1), 5.64 (d, 1H, H-2′), 7.35--7.75 (m, 10H, Ar-H), 10.28 (s, 1H, NH). Anal. calcd. for C~32~H~40~N~3~O~11~PS (705.71): C, 54.46; H, 5.71; N, 5.95; S, 4.54%. Found: C, 54.36; H, 5.65; N, 5.84; S, 4.42%.

4.4. Antiviral Screening Methods {#sec4.4}
--------------------------------

### 4.4.1. Cytotoxicity Test {#sec4.4.1}

It was done according to Simões et al.,^[@ref40]^ where samples (50 mg) were dissolved in 1 mL of DMSO. Decontamination of samples was done by adding 24 μL of 100× of the antibiotic--antimycotic mixture to 1 ML of each sample. Afterward, bifold dilutions were carried out to 100 μL of original dissolved samples and 100 μL of each dilutions was inoculated in Hep-2, Vero, BGM, FRHK4, and Huh 7.5 cell lines (obtained from the Holding Company for Biological Products & Vaccines VACSERA, Egypt) previously cultured in 96-multiwell plates (Greiner Bio-One, Germany) to estimate the nontoxic dose of the tested samples. Cytotoxicity assay was done through cell morphology evaluation using an inverted light microscope and cell viability test applying the trypan blue dye exclusion method.

### 4.4.2. Cell Morphology Evaluation by Inverted Light Microscopy {#sec4.4.2}

Hep-2, Vero, BGM, FRHK4, and Huh 7.5 cell cultures (2 × 10^5^ cells/mL) were prepared separately in 96-well tissue culture plates (Greiner Bio-One, Germany). After 24 h incubation at 37 °C in a humidified 5% (v/v) CO~2~ atmosphere, cell monolayers were confluent, and the medium was removed from each well and replenished with 100 μL of bifold dilutions of different samples tested prepared in DMEM (GIBCO BRL). For cell controls, 100 μL of DMEM without samples was added. All cultures were incubated at 37 °C in a humidified 5% (v/v) CO~2~ atmosphere for 72 h. Cell morphology was observed daily for microscopically detectable morphological alterations, such as loss of confluence, cell rounding and shrinking, and cytoplasm granulation and vacuolization. Morphological changes were scored (Simões et al.^[@ref40]^).

### 4.4.3. Cell Viability Assay {#sec4.4.3}

It was done through the trypan blue dye exclusion method (Walum et al.).^[@ref41]^ Hep-2, Vero, BGM, FRHK4, and Huh 7.5 cell cultures (2 × 10^5^ cells/mL) were grown in 12-well tissue culture plates (Greiner Bio-One, Germany). After 24 h incubation, the same assay described above for tested samples cytotoxicity was followed by applying 100 μL of tested samples dilutions (bifold dilutions) per well. After 72 h, the medium was removed, cells were trypsinized, and an equal volume of 0.4% (w/v) trypan blue dye aqueous solution was added to the cell suspension. Viable cells were counted under the phase contrast microscope.

### 4.4.4. Determination of Adenovirus 7, HAV HM175, Coxsackievirus B4, and Herpes Simplex Virus Type 1 Titers Using Plaque Assay {#sec4.4.4}

Nontoxic dilutions were mixed (100 μL) with 100 μL of different doses of adenovirus 7, HAV HM175, Coxsackievirus B4, and herpes simplex virus type 1 (1 × 10^5^, 1 × 10^6^, and 1 × 10^7^). The mixture was further incubated for half an hour at 37 °C. The inoculation of (100 μL) 10-fold dilutions of treated and untreated adenovirus 7, HAV HM175, Coxsackievirus B4, and herpes simplex virus type 1 was carried out separately into Hep-2, FRHK4, BGM, and Vero cell lines, respectively, in 12-multiwell plates. After 1 h of incubation for adsorption at 37 °C in a 5% CO~2~-water vapor atmosphere without constant shaking, the plates were shaken intermittently to keep the cells from drying. After adsorption, 1 mL of 2× media (Dulbecco's modified Eagle medium (DMEM), Gibco-BRL) plus 1 mL of 1% agarose was added to each well, and the plates were incubated at 37 °C in a 5% CO~2~-water vapor atmosphere. After the appropriate incubation period, the cells were stained with 0.4% crystal violet after formalin fixation, and the number of plaques was counted. The viral titers were then calculated and expressed as plaque-forming units per milliliter (pfu/mL) (Schmidtke et al.).^[@ref42]^ CC~50~ and IC~50~ were done for the promising materials (viral reduction of 50% or more). The 50% cytotoxic concentration (CC~50~) of the test extract was defined as the concentration that reduces the OD492 of treated uninfected cells to 50% of that of untreated uninfected cells. IC~50~ is the concentration at which the compound plaque reduction rate reaches halfway between the baseline and maximum.

### 4.4.5. Antiviral Bioassay of Tested Materials against ED-43/SG-Feo (VYG) Replicon of Hepatitis C Virus Genotype 4a {#sec4.4.5}

ED-43/SG-Feo (VYG) replicon of HCV genotype 4a was treated with the nontoxic dose of the tested materials. HCV RNA was quantified in algal extract-treated Huh 7.5-infected cells using qRT-PCR (Taqman probe kit, Qiagen) and according to the manufacturer's instructions to show a dose-dependent decrease in subgenomic RNA copies according to Saeed et al.^[@ref43]^
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